NEW YORK, Sept. 28, 2017 -- Nightstar Therapeutics plc (Nasdaq:NITE), a leading clinical-stage gene therapy company, rang the closing bell at the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/f735cbc8-df61-417e-9a3a-3dee84c8a5ed
http://www.globenewswire.com/NewsRoom/AttachmentNg/ea0abfbd-e1c2-43e7-9091-8d8c86fb60ce
Nightstar Therapeutics focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Through their expertise in ophthalmology, gene therapy and drug development, they are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments.
“Nightstar Therapeutics continues to innovate in life changing treatments,” said Nelson Griggs, President of the Nasdaq Stock Exchange, “We are extremely proud to partner with them as they continue to break barriers in the health care sector as a public company.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com.
Media Relations Contacts:
Stephanie Lowenthal
(646) 441-5073
[email protected]
Emily Pan
(646) 441-5120
[email protected]
- NDAQG -


Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 



